How to buy Adagene Inc stock (Adagene Inc)

Adagene Inc wrapped up its $139.73 million initial public offering, selling 7,354,000 American depositary shares at $19 each. The stock opened at $20.40 when trading began Tuesday and skyrocketed by more than 45% in early trading.

Our top picks for where to buy Adagene stock

Buy Adagene Inc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Adagene Inc stock price (NASDAQ: ADAG)

Use our graph to track the performance of ADAG stocks over time.

Adagene Inc shares at a glance

• Key figures

Information last updated 2024-12-15.

Latest market close	$2.05
52-week range	$1.60 - $4.38
50-day moving average more info button	$2.62
200-day moving average more info button	$2.76
Wall St. target price	$10.54
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.72

Is it a good time to buy Adagene Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adagene Inc price performance over time

Historical closes compared with the close of $2.01 from 2024-12-19

1 week (2024-12-13)	-2.43%
1 month (2024-11-21)	-11.06%
3 months (2024-09-20)	-16.25%
6 months (2024-06-20)	-35.16%

1 year (2023-12-20)	11.67%
2 years (2022-12-20)	74.78%
3 years (2021-12-20)	7.52
5 years (2019-12-17)	N/A

Adagene Inc financials

Revenue TTM	$815,746
Gross profit TTM	$10.2 million
Return on assets TTM	-19.59%
Return on equity TTM	-45.7%
Profit margin	0%
Book value	$1.28
Market Capitalization more info button	$108.5 million

TTM: trailing 12 months

Adagene Inc share dividends

We're not expecting Adagene Inc to pay a dividend over the next 12 months.

You may also wish to consider:

• Novo Nordisk A/S (NVO.US) (1.37% forward annual dividend yield)

Adagene Inc share price volatility

Over the last 12 months, Adagene Inc's shares have ranged in value from as little as $1.6 up to $4.38. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adagene Inc's is 0.577. This would suggest that Adagene Inc's shares are less volatile than average (for this exchange).

To put Adagene Inc's beta into context you can compare it against those of similar companies.

• Novo Nordisk A/S (NVO.US): 0.165
• Regeneron Pharmaceuticals (REGN.US): 0.142
• Alexion Pharmaceuticals (ALXN.US): 1.2595

Adagene Inc overview

Adagene Inc. , a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China. .

Frequently asked questions

null
What percentage of Adagene Inc is owned by insiders or institutions?
Currently 10.656% of Adagene Inc shares are held by insiders and 25.548% by institutions. How many people work for Adagene Inc?
Latest data suggests 174 work at Adagene Inc. When does the fiscal year end for Adagene Inc?
Adagene Inc's fiscal year ends in December. Where is Adagene Inc based?
Adagene Inc's address is: Building C14, Suzhou, China, 215123 What is Adagene Inc's ISIN number?
Adagene Inc's international securities identification number is: US0053291078